GSK Confident Its ‘Last Drug Standing’ In Anemia Class Can Gain US Panel Backing

Safety Profile Will Be Closely Scrutinized

 
• By Andrew McConaghie

GSK could have the US market to itself if it can convince the expert panel of daprodustat’s safety, as rivals have fallen by the wayside.

US FDA entrance sign
Daprodustat will be the third HIF-PHI reviewed by the FDA ad comm, GSK hoping its drug will succeed where rivals failed. • Source: Sutterstock, JHVEPhoto

More from New Products

More from Scrip